Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +91 22-69790010 from 9 AM - 5:30 PM IST

    • Contact
    • Contact

      +91 22-69790010
      from 9 AM - 5:30 PM IST

  • Request More Information
  • Journalists
  • Request More Information
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Request More Information
  • Journalists
  • Request More Information
  • Journalists

COVID Vaccine-Hesitant Consumers Care About Effectiveness Over Side-Effects
  • USA - English


News provided by

Conjoint.ly

07 May, 2021, 09:45 IST

Share this article

Share toX

Share this article

Share toX

New study shows that UK and USA consumers want a free and effective COVID-19 vaccine, and care more about effectiveness and accessibility than risk of side-effects.

SYDNEY, May 7, 2021 /PRNewswire/ -- Market research software company Conjoint.ly today released results from its recent Consumer Preferences for COVID-19 Vaccine conjoint analysis survey, revealing that vaccine-hesitant consumers in the UK and US are most likely to be swayed by a fully-subsidised vaccine that has at least 85% effectiveness - comparable to results from a similar Chinese study.

Conjoint.ly's research, conducted between 31 March and 5 April 2021, takes inspiration from academics Leng et al's January 2020 conjoint study Individual preferences for COVID-19 vaccination in China, which also found that Chinese respondents are more willing to take the vaccine if it is free and highly effective.

"Countries around the world face similar challenges with vaccine rollouts. We were intrigued by conjoint research from China around factors of vaccine adoption. Our research showed that communicating vaccine effectiveness works well to convince people to take the jab in the West, as it does in the East," said Conjoint.ly's Founder, Nik Samoylov.

Both studies assessed respondents' vaccine preferences based on several factors, such as effectiveness and accessibility to determine which vaccine characteristics would encourage the highest uptake rates in each country. The conjoint surveys also presented respondents with choices surrounding risk of side-effects, duration of protection, number of doses required, and number of acquaintances already vaccinated.

About Conjoint.ly: Conjoint.ly is an online service for pricing and product research using state-of-the-art discrete choice methods (conjoint analysis), Van Westendorp, Gabor-Granger, monadic concept testing, and other techniques. Conjoint analysis is a popular market research methodology which helps to reveal consumers' preferences by presenting respondents with several product concepts much like in a real-life setting.

Catherine Chipeta, Conjoint.ly
Phone: +61-416-504-345
Email: [email protected]

Further information: https://conjointly.com/blog/covid-vaccine-consumer-survey

Related Files

202103_March_Omnibus_COVID-19_Consumer_Preferences[1].pdf

Related Images

vaccine-attribute-importance-for.png
Vaccine attribute importance for UK and USA consumers
The Conjoint.ly study found the most important attributes to be high vaccine effectiveness, low risk of side effects and a long period of protection - even among vaccine-hesitant people in UK and USA.

Modal title

Contact PR Newswire

  • +91 22-69790010

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+91 (0) 22 6169 6000
from 9 AM - 5:30 PM IST
  • Terms of Use
  • Privacy Policy
  • GDPR
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.